BHCM
ZBIO

Brevan Howard Capital Management’s Zenas BioPharma ZBIO Stock Holding History

Brevan Howard Capital Management’s Portfolio ZBIO Stock Details ZBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-6,173
Closed -$224K – 2572
2025
Q4 		$224K Buy
+6,173
New +$203K ﹤0.01% 1523

Other funds holding ZBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $176M AUM 208.78% 1-Year Est. Return

Brevan Howard Capital Management's ZBIO Position: Q1 2026 in Review

Brevan Howard Capital Management sold out of Zenas BioPharma (ZBIO) in Q1 2026, closing a stake of 6,173 shares — an estimated $224K sold.

Brevan Howard Capital Management first reported a position in ZBIO in Q4 2025 and held it in 1 quarter. The position peaked at $224K in Q4 2025. 139 funds tracked by Wall St. Rank hold ZBIO as of Q1 2026.

  • Brevan Howard Capital Management reported no remaining Zenas BioPharma position as of Q1 2026 after selling out during the quarter.
  • Brevan Howard Capital Management sold 6,173 Zenas BioPharma shares in Q1 2026, an estimated $224K.
  • Brevan Howard Capital Management first reported a position in Zenas BioPharma in Q4 2025 and held it in 1 quarter.
  • Brevan Howard Capital Management's Zenas BioPharma position peaked at $224K in Q4 2025.
  • 139 funds tracked by Wall St. Rank held Zenas BioPharma as of Q1 2026.

Based on Brevan Howard Capital Management's 13F filing for Q1 2026, filed 15 May 2026.